Vascepa is a prescription medication used to reduce the risk of cardiovascular events in adults with elevated triglyceride levels. According to Drug Patent Watch [1], Vascepa contains the active ingredient eicosapentaenoic acid (EPA), which is an omega-3 fatty acid found in fish oil. The recommended dosage of Vascepa is two grams taken orally twice daily with food. The medication is usually taken for an extended period, and the duration of treatment depends on the individual's medical condition.
According to Healthline [2], clinical studies have shown that taking Vascepa for at least five years can provide optimal results in reducing the risk of cardiovascular events. The study showed that taking Vascepa for five years reduced the risk of cardiovascular events by 25%. However, the study also revealed that the risk reduction increased with the duration of treatment, and taking Vascepa for more than five years could provide even better results.
Another study published in Harvard Health Blog [3] stated that the optimal duration of Vascepa treatment is not yet known. The study noted that the benefits of Vascepa were seen after just one year of treatment, but the long-term effects are still unclear. The study also stated that the benefits of Vascepa may vary depending on the individual's medical condition, and a doctor should be consulted to determine the optimal duration of treatment.
In conclusion, the optimal duration of Vascepa treatment depends on the individual's medical condition and should be determined by a doctor. However, clinical studies have shown that taking Vascepa for at least five years can provide optimal results in reducing the risk of cardiovascular events. The long-term effects of Vascepa are still unclear, and further research is needed to determine the optimal duration of treatment.
Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.healthline.com/health/drugs/vascepa
[3] https://www.health.harvard.edu/blog/omega-3-fatty-acids-and-the-heart-new-evidence-more-questions-2021032422213